Clinical Trials

Amgen’s olpasiran reduces cardiovascular disease risk factor in Phase II study

Amgen has reported positive end-of-treatment data from the Phase II OCEAN(a)-DOSE study of its investigational olpasiran (formerly AMG 890).

Erasca, Eli Lilly partner for colorectal cancer therapy trial

Erasca and Eli Lilly and Company have signed a clinical trial partnership and supply agreement to evaluate ERAS-007, an oral ERK1/2 inhibitor, in combination with Eli Lilly's anti-EGFR antibody cetuximab (ERBITUX).

US FDA approves Avacta Group’s IND application for AVA6000

The US Food and Drug Administration (FDA) has granted approval to Avacta Group’s Investigational New Drug (IND) application for AVA6000, a new form of doxorubicin.

Moleculin receives approval to start trial of WP1122 for Covid-19 in UK

Moleculin Biotech has received authorisation to begin a Phase Ia clinical trial of its drug, WP1122, in the UK to treat Covid-19.

Pfizer begins Phase I clinical trial of mRNA influenza vaccine

Pfizer has dosed the first subjects in a Phase I clinical trial to test an influenza vaccine which is developed using mRNA technology.

Hookipa, Merck partner for Phase II HB-200/Keytruda combination trial

Hookipa Pharma has signed a clinical collaboration and supply agreement with Merck to assess HB-200 in combination with Keytruda (pembrolizumab) in patients with advanced head and neck squamous cell carcinoma (HNSCC).

EnGeneIC begins Phase I trial of nanocellular vaccine for Covid-19

EnGeneIC has started dosing in Phase I clinical trial of the world’s first nanocellular technology-based anti-Covid-19 vaccine in healthy adults.

Centivax signs strategic collaboration with US NMRC for Covid-19 antibody

Centivax has inked a strategic collaboration with the US Naval Medical Research Center (NMRC) to carry out Phase I trial of Centi-B9, its SARS-CoV-2 antibody.

Study finds PARP inhibitors kill cancer cells with defect in PBRM1 gene

A study, conducted by The Institute of Cancer Research, London (ICR) and Paris-based cancer research institute Gustave Roussy, identified that drugs known as PARP inhibitors kill cancer cells with a particular defect in the PBRM1 gene.